Given the modest benefits of adjuvant and/or risk reduction endocrine therapy in patients with ER+ DCIS, in terms of reducing the risk of an ipsilateral in-breast recurrence following surgery and radiation and reducing the risk of a contralateral estrogen receptor-positive breast cancer, and the abs...